Back to list

Phase II M2951 study for Systemic Lupus Erythematosus (SLE)

University of North Carolina at Chapel Hill


To possibly help reduce symptoms associated with Systemic Lupus Erythematosus (SLE).


Arthritis, Auto Immune Diseases, Joints, Lupus, Skin


Drug or Biologic



18 - 75 years


Study Population

This study is looking for patients diagnosed with Systemic Lupus Erythamtosus (SLE) with active symptoms ex. arthritis, rash, mucosal ulcers, alopecia


Saira Sheikh
Clinical Assistant Professor
Medicine-UNCP A Rheumatology

For questions, contact:

Julie Walker
(919) 843-6619

Recruitment Period End

May 31, 2019


Primary Location
UNC Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 75 years

Participant qualification(s) Female subjects of child bearing potential must no be pregnant or nursing and must be on 2 methods of birth control. Diagnosed with SLE at least 6 months ago Currently has active symptoms associated with SLE and be on stable therapy.

Not eligible if: Class III or IV pulmonary hypertension. History of moderate to severe cardiac issues Active Lupus Nephritis Diagnosis of Interstitial Lung Disease Seizure activity currently of within past 2 years Steroids (prednisone) greater than 30mg Medications will be reviewed in detail by study coordinator

Number of Visits

    » 20 In person visit(s)

    1 screening, 19 clinic

    » 0 Remote visit(s)

Participation Period

1 year with possibility of long term extension


By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.